Takeda Begins Own Development Of RNAi-Based Cancer Drugs
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical is using technology it bought from U.S.-based Alnylam Pharmaceuticals to develop cancer treatments based on RNA interference, a method of blocking unwanted genes in cells